SRC and ovarian carcinoma: To determine if the activation of Src can be upregulated in ovarian cancer cells in response to chemotherapy and to mimic the profile seen in the ascites-derived tumour cells of chemotherapy treated patients, the HEY ovarian cancer cell line was subjected to IC50 concentration of paclitaxel (0.05 μg/mL) for 6, 24 and 72 h (Supplementary Figure S1).